Key Highlights

  • Innventure (NASDAQ:INV) gained 9.66% to USD 0.3200 in pre-market trading on Tuesday, October 27, 2026, with an at-the-market programme of up to USD 60 million that replaced a standby equity purchase agreement.
  • Tempest Therapeutics (NASDAQ:TPST) rose 5.84% to USD 0.5400 with no announced facility, but cash of USD 0.8 million at June 30, 2026 points to a need for new capital.
  • BioCardia (NASDAQ:BCDA) rose 5.62% to USD 0.9522, after FDA acceptance of a pre-submission package, with cash of USD 4.1 million supported by at-the-market sales.
  • Propanc Biopharma (NASDAQ:PPCB) fell 6.11% to USD 2.15 in the first session after a 1-for-10 reverse split, with a Series C preferred facility of up to USD 100 million adding potential supply.

Innventure (NASDAQ:INV): a USD 60 million programme at the company's discretion

Innventure (NASDAQ:INV), a company with two subsidiaries, Accelsius (two-phase cooling for data centres) and Refinity (plastic-to-olefins recycling), traded in a pre-market snapshot. No company-specific announcement dated Tuesday, October 27, 2026 accompanied the move. The most recent release, dated Thursday, October 8, 2026, established the at-the-market equity programme, a mechanism that lets a company sell shares gradually into the market, and discontinued the standby equity purchase agreement with YA II PN. The gain appears consistent with thin pre-market liquidity and a rebound in a low-priced stock.

In the release of Thursday, August 13, 2026, second-quarter 2026 revenue was USD 953 thousand and the net loss was USD 34.9 million. Cash and equivalents were USD 41.5 million, and six-month cash used in operations was USD 59.5 million, funded in part by USD 50.2 million of equity raised. The company targeted parent quarterly cash expenses of about USD 3.2 million by year-end 2026, down from USD 7.5 million at the start of 2026.

The company is under no obligation to sell shares under the programme, so dilution depends on usage. Because the shares trade below USD 1.00, a minimum bid price shortfall is a named risk. The company also suspended its 2026 revenue and cash flow expectations for Accelsius.

Tempest Therapeutics (NASDAQ:TPST): an unfunded gap at a sub-dollar price

Tempest Therapeutics (NASDAQ:TPST), a clinical-stage oncology company developing small molecules and an antibody-based asset, traded in a pre-market snapshot. No company-specific announcement dated on or just before Tuesday, October 27, 2026 accompanied the move. The advance therefore appears consistent with thin pre-market liquidity, where few orders can shift the quote. The most recent company communication is the release of Thursday, August 13, 2026, which covered the quarter ended June 30, 2026.

That release reported a net loss of USD 5.2 million, or USD 0.34 per share, against USD 7.9 million a year earlier. Research and development expense was USD 1.8 million, down from USD 3.9 million, mainly because of lower spending after the February 2026 asset acquisition. Cash and equivalents were USD 0.8 million, against USD 7.7 million on December 31, 2025, and the year-end report of Monday, March 30, 2026 cited a need for additional capital.

Tempest shows the driver before any facility is described: the funding need is stated, while the instrument is not. The bear reading rests on cash against the quarterly loss and on Nasdaq minimum bid price compliance. The bull reading rests on pipeline milestones planned for 2026, including a potentially registrational study of TPST-2003 in relapsed or refractory multiple myeloma. Reliance on partners for several programmes adds risk.

BioCardia (NASDAQ:BCDA): at-the-market sales extending the runway

BioCardia (NASDAQ:BCDA), a clinical-stage company developing autologous cell therapy for cardiovascular disease and the Helix transendocardial delivery catheter, traded in a pre-market snapshot. No company-specific announcement dated Tuesday, October 27, 2026 was identified. The most recent catalyst is the company's release of Monday, October 19, 2026, which stated that the FDA accepted a revised De Novo pre-submission package for Helix and described it as not marketing clearance. The move therefore appears consistent with a delayed reaction and thin liquidity.

The company's release of Wednesday, August 12, 2026 reported a net loss of USD 1.6 million for the quarter ended June 30, 2026 and operating cash use of USD 1.7 million. Cash and equivalents were USD 4.1 million after USD 4.9 million raised through an at-the-market offering. The financing release of Monday, June 8, 2026 reported USD 4.4 million from the sale of 3,509,604 shares at an average USD 1.279, with no new warrants, and said net proceeds should extend runway into the first quarter of 2027. The two amounts come from different company releases.

BioCardia illustrates the programme in use, with regulatory steps and funding moving together. The bear reading rests on a runway stated only into the first quarter of 2027, with dilution, regulatory delay and bid price pressure as named risks. A Japanese marketing approval submission is expected in the fourth quarter of 2026.

Propanc Biopharma (NASDAQ:PPCB): a preferred facility after a reverse split

Propanc Biopharma (NASDAQ:PPCB), a clinical-stage biotechnology company developing a therapy for solid tumours, traded in the first session after a 1-for-10 reverse stock split, a corporate action that consolidates every ten shares into one, effective Monday, October 26, 2026. The announcement was framed as supporting continued Nasdaq listing, which requires a minimum bid price of USD 1.00 per share. Pre-market trading in the first session after a split is often uneven because quotes are reset and liquidity is thin. The move appears consistent with that adjustment process, and the reverse split is the only company-specific event dated on or just before the session. The detailed terms of the notice are not set out here.

The company's release of Tuesday, September 29, 2026 reported results for the fiscal year ended June 30, 2026. The net loss was USD 18,862,710 against USD 58,923,300 a year earlier, and cash was USD 832,006, against USD 12,088 a year earlier. Financing in the period included an underwritten offering of 1,000,000 shares at USD 4.00 and a Series C preferred facility of up to USD 100 million.

A facility of that size set against thin cash implies continued issuance of equity, and repeated reverse splits are a named risk. The lead candidate PRP is planned to enter a Phase 1b study of up to 50 patients in Australia, with first patient dosing planned for April 2027.

Where Things Stand

The answer is that shelf and at-the-market dilution weighs on all four names, yet the pre-market moves track thin liquidity and procedural news more than the facilities themselves. Innventure (NASDAQ:INV) holds an unused programme, Tempest Therapeutics (NASDAQ:TPST) has a funding gap without a described instrument, BioCardia (NASDAQ:BCDA) has used its programme to extend runway and Propanc Biopharma (NASDAQ:PPCB) carries a large preferred facility after a share consolidation.

The next catalysts are the Federal Reserve decision on Wednesday, October 28, 2026, FDA written feedback at BioCardia, the ethics committee submission at Propanc in November 2026 and the third quarter reports of Innventure and Tempest. Pre-market prices are snapshots and can change before the open at 9:30 a.m. ET, and this is not investment advice.